On June 30, 2022, the Board of Directors of BioXcel Therapeutics, Inc. appointed Michael Miller to the Board, effective July 1, 2022. Miller will serve as a Class II director for a term expiring at the Company's annual meeting of stockholders to be held in 2023 and until his successor is duly elected and qualified or his earlier death, disqualification, resignation or removal. In connection with his appointment, Miller was also appointed to the Audit Committee, effective with his commencement of service.

Miller, 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. Prior to that, he served as Executive Vice President, Commercial of Jazz Pharmaceuticals plc from March 2014 to August 2020. Since May 2018, Miller has served on the Board of Puma Biotechnology Inc., where he also serves on the Compensation Committee.

Miller received his B.S. from the University of San Francisco and his M.B.A. from San Francisco State University. The Board believes that Miller's extensive experience at commercial pharmaceutical and public companies will be valuable contributions to the Board. Miller is expected to enter into the Company's standard indemnification agreement for directors and officers.